Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Published:2012-01-19 Issue:5 Volume:138 Page:745-751
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Qi Wei-Xiang,Tang Li-Na,He Ai-Na,Shen Zan,Yao Yang

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-012-1155-9.pdf

Reference26 articles.

1. Arrieta O, Villarreal-Garza C, Pachuca D et al (2011) High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. Med Oncol 8:300–306

2. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

3. Chiappori A, Bepler G, Barlesi F et al (2010) Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 5:369–375

4. de Boer RH, Arrieta Ó, Yang CH et al (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29:1067–1074

5. Di Maio M, Chiodini P, Georgoulias V et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients;Respiratory Investigation;2020-07

2. Systemic Options for Second-Line Therapy and Beyond;IASLC Thoracic Oncology;2018

3. Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer;Hematology/Oncology Clinics of North America;2017-02

4. Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer;BMC Medicine;2016-01-20

5. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis;Drug Design, Development and Therapy;2015-07